1. Saxena K, et al. Pharmacokinetics, efficacy, and safety of BAY 81-8973, a full-length plasma-protein-free recombinant factor VIII product: results from the LEOPOLD trial. J Thromb Haemost 2013;11(S2):290–1019, PB 4.37–2.
2. Kavakli K, et al. Prophylaxis vs. on-demand treatment with BAY 81–8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). J Thromb Haemost 2015;13:360–9.
3. Ljung R, et al. BAY 81–8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial. Haemophilia published online December 9, 2015; doi: 10.1111/hae. 12866. [Epub ahead of print].